PATIENTS:
42 middle-aged women with non-rheumatic joint pain. Half the patients
were given 5 Rose-Hip Vital capsules twice daily, the other half identical
placebos over a three month period. Then the original group taking Rose-Hip
Vital were changed to placebo and vice versa for another three months.
Investigation was performed at the beginning and at the end of each of
the two treatment periods. This was a randomised, double-blind cross-over
test.
AIM: To investigate whether Rose-Hip Vital can reduce pain and
stiffness in middle-aged women suffering from non-rheumatic joint pain.
To test if a reduction in pain, if present, would affect the patient’s
daily activities. To investigate if patients evaluation of the severity
of their disease was changed by treatment.
CONCLUSION:
While on Rose-Hip Vital pain and stiffness significantly declined by approximately 50%. When the 21 patients who
were given Rose-Hip Vital before the placebo were evaluated separately,
the results were even more in favour of Rose-Hip Vital. This suggests
a carry-over affect. Patients Global Assessment of Disease Severity (PGADS)
also significantly declined and thus an improvement in various daily activities
resulted. No patients reported any side effects.
TEST CONDUCTED BY: Rein E, Kharazmi A, Winther K. At the Department
of Clinical Research, Kolding; Department of Clinical Microbiology, Rigs
Hospital; Department of Clinical Biochemistry, Copenhagen County Hospital;
and University of Copenhagen, Denmark.
Written
and conceived by Christian Dige.
Website by
www.visiontechsolutions.com.au
Copyright
© Rose-Hip Vital.